Publications by authors named "L Bertin"
Crohn's disease (CD) is a chronic, complex inflammatory disorder of the gastrointestinal tract that presents significant therapeutic challenges. Despite the availability of a wide range of treatments, many patients experience primary non-response, secondary loss of response, or adverse events, limiting the overall effectiveness of current therapies. Clinical trials often report response rates below 60%, partly due to stringent inclusion criteria.
View Article and Find Full Text PDFEditorial: Targeting the Future of Eosinophilic Oesophagitis Management.
Aliment Pharmacol Ther
December 2024
JAK Inhibitors: A Double-Edged Sword in Immune-Mediated Diseases Management.
United European Gastroenterol J
November 2024
JAK inhibitors are pivotal in treating immune-mediated inflammatory diseases (IMIDs) like rheumatoid arthritis (RA) and inflammatory bowel disease. However, emerging safety concerns warrant careful evaluation. A recent analysis of the FDA Adverse Event Reporting System (FAERS) revealed that RA patients using JAK inhibitors face nearly double the risk of gastrointestinal perforations (GIPs) compared to those on biologics, particularly with concurrent steroid or NSAID use.
View Article and Find Full Text PDFArticle Synopsis
- A systematic review was conducted to evaluate functional performance (FP) instruments for chronic respiratory diseases (CRD) other than chronic obstructive pulmonary disease (COPD), highlighting the challenge of selecting the right tool.
- The review found and analyzed 216 studies across seven types of CRD, identifying 33 different FP instruments, with the SF-36 questionnaire and the 1-minute sit-to-stand test being the most commonly used.
- Despite the widespread use of these instruments, there is limited data on their measurement properties and clinical significance, making this review essential for guiding clinical choices in non-COPD CRD.
Can the use of iron phthalocyanine-derivative mouthrinses in COVID-19 patients provide systemic benefits? Research into this potential should be considered.
GMS Hyg Infect Control
October 2024
Aim: The purpose of this brief report is to discuss the impact of an oral rinse and spray containing an iron phthalocyanine derivative as an additional therapy in hospitalized COVID-19 patients.
Methods: In the first study by this group of authors published on this topic, the clinical status of 22 patients with COVID-19 who were hospitalized and receiving PDMS (phthalocyanine derivative mouth spray) was assessed using the Karnofsky scale (KS) for thtree days (D0, D2, and D4). In another study, the laboratory data (CBC, D-dimer, Ferritin, and C-reactive protein [CRP]) of 41 patients hospitalized with COVID-19 who took part in a randomized clinical trial with an MIPD (mouthwash with iron phthalocyanine derivative) were evaluated retrospectively on the first day of intervention (D1) and 48 hours later (D2).